New brain tumor drug shows early promise in small study
NCT ID NCT05577416
First seen Mar 22, 2026 · Last updated May 14, 2026 · Updated 7 times
Summary
This study tested an experimental drug called AB-218 in 14 people with a specific type of slow-growing brain tumor (IDH1 mutated low-grade glioma) who were already scheduled for surgery. The main goals were to see if it's possible to run this kind of study and to measure how much of the drug reaches the tumor and spinal fluid. Researchers also tracked side effects to understand the drug's safety.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Royal Melbourne Hospital
Melbourne, Victoria, Australia
Conditions
Explore the condition pages connected to this study.